Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

被引：38

作者：

Tuccori, Marco ^{[1
]}

Focosi, Daniele ^{[2
]}

Blandizzi, Corrado ^{[1
,5
]}

Pelosini, Matteo ^{[2
]}

Montagnani, Sabrina ^{[1
,5
]}

Maggi, Fabrizio ^{[3
,4
]}

Pistello, Mauro ^{[3
,4
]}

Antonioli, Luca ^{[1
]}

Fornai, Matteo ^{[1
]}

Pepe, Pasquale ^{[6
]}

Rossi, Giuseppe ^{[6
]}

Petrini, Mario ^{[2
]}

机构：

[1] Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Pisa, Italy

[2] Univ Pisa, Div Haematol, Dept Oncol Transplantat & New Technol Med, Pisa, Italy

[3] Univ Pisa, Virol Sect, Pisa, Italy

[4] Univ Pisa, Retrovirus Ctr, Dept Expt Pathol, Pisa, Italy

[5] Tuscan Reg Ctr Pharmacovigilance, Pisa, Italy

[6] CNR, Unit Epidemiol & Biostat, Inst Clin Physiol, Pisa, Italy

来源：

ONCOLOGIST | 2010年 / 15卷 / 11期

关键词：

Rituximab; Progressive multifocal leukoencephalopathy; JCV; Monoclonal antibody; Non-Hodgkin's lymphoma; ADVERSE DRUG EVENTS; NATALIZUMAB; EFALIZUMAB; THERAPY; PROJECT; DISEASE; PML;

D O I：

10.1634/theoncologist.2010-0098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives. Rituximab is an anti-CD20 monoclonal antibody that promotes better treatment outcomes in patients with non-Hodgkin's lymphoma (NHL). Case series of progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab within polychemotherapy regimens have led to the introduction of a black box warning, but no risk estimation has ever been provided. Methods. We performed a retrospective, monocentric cohort study on 976 NHL patients diagnosed in 1994-2008, including 517 patients who received at least one dose of rituximab. Results. Inclusion of rituximab into standard chemotherapy regimens for NHL caused a significantly higher incidence of PML cases (rate difference, 2.2 every 1,000 patient-years; 95% confidence interval, 0.1-4.3). Interpretation. Based on this finding, clinical surveillance of PML-related symptoms is recommended in NHL patients exposed to rituximab. The Oncologist 2010;15:1214-1219

引用

页码：1214 / 1219

页数：6

共 50 条

[21] Recent Advances in the Treatment of Non-Hodgkin's Lymphomas [J].

Abramson, Jeremy S. ;

Zelenetz, Andrew D. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (5.5) :671-675

[22] Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma [J].

Fernandez-Canabate, Eva ;

Fernandez-Canabate, Sonia .

FARMACIA HOSPITALARIA, 2018, 42 (01) :20-21

[23] Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas [J].

Gabellier, Ludovic ;

Cartron, Guillaume .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (02) :85-93

[24] Reply to Magnetic Resonance Imaging-Based Diagnosis of Progressive Multifocal Leukoencephalopathy in a Patient With Non-Hodgkin Lymphoma After Therapy With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab [J].

Bennett, Charles L. ;

Newsome, Scott D. ;

Sartor, Oliver ;

Carson, Kenneth R. .

CANCER, 2014, 120 (24) :4006-4007

[25] Obinutuzumab for the treatment of non-Hodgkin lymphomas [J].

Hernandez, Juana ;

Nielsen, Tina ;

Klein, Christian ;

Wenger, Michael .

NATURE, 2018, 563 (7731)

[26] Progressive Multifocal Leukoencephalopathy Following Rituximab Treatment in a Patient With Rheumatoid Arthritis [J].

Fleischmann, R. M. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (11) :3225-3228

[27] Management of non-Hodgkin's lymphomas [J].

Mounter, PJ ;

Lennard, AL .

POSTGRADUATE MEDICAL JOURNAL, 1999, 75 (879) :2-6

[28] Non-Hodgkin's lymphomas of the colon [J].

Bairey, Osnat ;

Ruchlemer, Rosa ;

Shpilberg, Ofer .

ISRAEL MEDICAL ASSOCIATION JOURNAL, 2006, 8 (12) :832-835

[29] Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study [J].

Ternant, David ;

Monjanel, Helene ;

Venel, Yann ;

Prunier-Aesch, Caroline ;

Arbion, Flavie ;

Colombat, Philippe ;

Paintaud, Gilles ;

Gyan, Emmanuel .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) :2002-2010

[30] Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas [J].

Sharma, P. ;

King, G. T. ;

Shinde, S. S. ;

Purev, E. ;

Jimeno, A. .

DRUGS OF TODAY, 2018, 54 (03) :187-198

← 1 2 3 4 5 →